597545-16-9

Upstream product

• 463-71-8 thiophosgene 
• 6358-77-6 5-bromo-2-methoxyaniline 

Downstream Products

• 1377581-20-8 1-{5-[3-(2',4'-Dimethyl-[4,5']bithiazolyl-2-ylamino)-4-methoxy-phenyl]-thiophen-2-yl}-ethanone 
• 1377581-85-5 (2',4'-Dimethyl-[4,5']bithiazolyl-2-yl)-[2-methoxy-5-(4,4,5,5-tetramethyl[1,3,2]dioxaborolan-2-yl)-phenyl]-amine 
• 1377581-21-9 (2',4'-Dimethyl-[4,5']bithiazolyl-2-yl)-[5-(3,5-dimethyl-isoxazol-4-yl)-2-methoxy-phenyl]-amine 
• 1377581-84-4 (5-bromo-2-methoxy-phenyl)-(2',4'-dimethyl-[4,5']bithiazolyl-2-yl)-amine 

Relevant academic research and scientific papers

BISTHIAZOLE INHIBITORS OF PRO-MATRIX METALLOPROTEINASE ACTIVATION

This invention relates to bisthiazole I and its therapeutic and prophylactic uses, wherein the variables A, R5, R6, and R7 are defined in the specification. Disorders treated and/or prevented include rheumatoid arthritis.

TRICYCLIC INHIBITORS OF PRO-MATRIX METALLOPROTEINASE ACTIVATION

This invention relates to tricycle I and its therapeutic and prophylactic uses, wherein the variables C1, C2, Z1, Z2, Q, J, R1, and R3 are defined in the specification. Disorders treated and/or prevented include rheumatoid arthritis.

METHODS OF INHIBITING PRO MATRIX METALLOPROTEINASE ACTIVATION

This invention relates to methods for preventing, treating or ameliorating an MMP9 and/or MMP13 mediated syndrome, disorder or disease comprising administering to a subject in need thereof an effective amount of a compound listed in the examples section of this specification, or a form, composition or medicament thereof. Disorders treated and/or prevented include rheumatoid arthritis.

Substituted benzazoles and methods of their use as inhibitors of Raf kinase

New substituted benz-azole compounds, compositions and methods of inhibition of Raf kinase activity in a human or animal subject are provided. The new compounds compositions may be used either alone or in combination with at least one additional agent for the treatment of a Raf kinase mediated disorder, such as cancer.